drugset / Trial / NCT07457125
The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease
Phase 1/2
Recruiting
33 enrolled
Xuanwu Hospital, Beijing
Carrier Biomed (Suzhou) Co., Ltd · collabInstitute of Process Engineering, Chinese Academy of Sciences · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized, double-blind, placebo-controlled study.
Timeline
- Start
- 2026-05-30
- Primary completion
- 2028-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exosomes derived from umbilical cord mesenchymal stem cell | Other / unclassified | 7.5e+09 unknown | Intranasal |
| Subject | Exosomes derived from umbilical cord mesenchymal stem cell | Other / unclassified | 1.5e+10 unknown | Intranasal |
| Subject | Exosomes derived from umbilical cord mesenchymal stem cell | Other / unclassified | 3e+10 unknown | Intranasal |
Indications
No indication recorded.